Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

Informatics on Drug Repurposing for Breast Cancer.

Computational Drug Repositioning for Cancer Therapeutics

Computer-aided Drug Repurposing for Cancer Therapy: Approaches and Opportunities to Challenge Anticancer Targets

Artificial intelligence, machine learning, and drug repurposing in cancer

A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds

Computationally repurposing drugs for breast cancer subtypes using a network-based approach

In silico approaches for drug repurposing in oncology: a scoping review

Drug repurposing—an emerging strategy in cancer therapeutics

A Review of Recent Developments and Progress in Computational Drug Repositioning.

Repositioning Drugs For Breast Cancer Based On The Identification Of Cancer Related Signaling Pathways

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Computational drug repositioning: from data to therapeutics.

An Analytical Review of Computational Drug Repurposing

Biomedical Data and Computational Models for Drug Repositioning: a Comprehensive Review

Repurposing of Drugs: Updates and New Perspectives

Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions

Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network

Overcoming cancer therapeutic bottleneck by drug repurposing

Drug Repurposing by Integrated Literature Mining and Drug-Gene-Disease Triangulation